Novartis, Incyte will take Jakafi into 2nd trial for COVID-19 patients on ventilators

5th May 2020 Uncategorised 0

Novartis and Incyte have already pitted their blockbuster JAK inhibitor Jakafi against COVID-19 as a possible treatment for a severe respiratory immune reaction. Now, seeing promise in another category of coronavirus-afflicted patients, the partners will take Jakafi into a second late-stage trial. 

More: Novartis, Incyte will take Jakafi into 2nd trial for COVID-19 patients on ventilators
Source: fierce